Tyrosine kinase inhibitors

A compound of Formula I:

• or a pharmaceutically acceptable salt or stereoisomer thereof, wherein
• a is 0 or 1;
• b is 0 or 1;
• m is 0, 1, or 2;
• R1 is selected from:
• 1) aryl,
• 2) C3–C5 cycloalkyl;
• 3) C2–C3 alkenyl;
• 4) C2–C3 alkynyl and
• 5) heteroaryl,
• said aryl, cycloalkyl and heteroaryl is optionally substituted with one or more substituents selected from R3;
• R2 is selected from:
• 1) aryl,
• 2) C3–C8 cycloalkyl and
• 3) heterocyclyl,
• said aryl, cycloalkyl and heterocyclyl is optionally substituted with one or more substituents selected from R4;
• R3 is:
• 1) (C═O)aObC1–C3 alkyl,
• 2) CO2H,
• 3) halo,
• 4) CN,
• 5) OH,
• 6) ObC1–C3 perfluoroalkyl,
• 7) Oa(C═O)bNH2,
• 8) oxo,
• 9) CHO, or
• 10) (N═O)H2;
• R4 is:
• 1) (C═O)aObC1–C10 alkyl,
• 2) (C═O)aObaryl,
• 3) C2–C10 alkenyl,
• 4) C2–C10 alkynyl,
• 5) (C═O)aOb heterocyclyl,
• 6) CO2H,
• 7) halo,
• 8) CN,
• 9) OH,
• 10) ObC1–C6 perfluoroalkyl,
• 11) Oa(C═O)bNR6R7,
• 12) oxo,
• 13) CHO,
• 14) (N═O)R6R7, or
• 15) (C═O)aObC3–C8 cycloalkyl,
• said alkyl, aryl, alkenyl, alkynyl, heterocyclyl, and cycloalkyl optionally substituted with one or more substituents selected from R5;
• R5 is selected from:
• 1) (C═O)rOs(C1–C10)alkyl, wherein r and s are independently 0 or 1,
• 2) Or(C1–C3)perfluoroalkyl, wherein r is 0 or 1,
• 3) (C0–C6)alkylene-S(O)mRa, wherein m is 0, 1, or 2,
• 4) oxo,
• 5) OH,
• 6) halo,
• 7) CN,
• 8) (C2–C10)alkenyl,
• 9) (C2–C10)alkynyl,
• 10) (C3–C6)cycloalkyl,
• 11) (C0–C6)alkylene-aryl,
• 12) (C0–C6)alkylene-heterocyclyl,
• 13) (C0–C6)alkylene-N(Rb)2,
• 14) C(O)Ra,
• 15) (C0–C6)alkylene-CO2Ra,
• 16) C(O)H, and
• 17) (C0–C6)alkylene-CO2H,
• said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heterocyclyl is optionally substituted with up to three substituents selected from Rb, OH, (C1–C6)alkoxy, halogen, CO2H, CN, O(C═O)C1–C6 alkyl, oxo, and N(Rb)2;
• R6 and R7 are independently selected from:
• 1) H,
• 2) (C═O)ObC1–C10 alkyl,
• 3) (C═O)ObC3–C8 cycloalkyl,
• 4) (C═O)Obaryl,
• 5) (C═O)Obheterocyclyl,
• 6) C1–C10 alkyl,
• 7) aryl,
• 8) C2–C10 alkenyl,
• 9) C2–C10 alkynyl,
• 10) heterocyclyl,
• 11) C3–C8 cycloalkyl,
• 12) SO2Ra, and
• 13) (C═O)NRb2,
• said alkyl, cycloalkyl, aryl, heterocylyl, alkenyl, and alkynyl is optionally substituted with one or more substituents selected from R5, or
• R6 and R7 can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5–7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, said monocyclic or bicyclic heterocycle optionally substituted with one or more substituents selected from R5;
• Ra is (C1–C6)alkyl, (C3–C6)cycloalkyl, aryl, or heterocyclyl;
• and
• Rb is H, (C1–C6)alkyl, aryl, heterocyclyl, (C3–C6)cycloalkyl, (C═O)OC1–C6 alkyl, (C═O)C1–C6 alkyl or S(O)2Ra.